Patients with Squamous Cell Carcinoma of the Head and Neck

[1]  David J. Yang,et al.  Assessment of epidermal growth factor receptor with 99mTc–ethylenedicysteine–C225 monoclonal antibody , 2003, Anti-cancer drugs.

[2]  J. Grandis,et al.  Targeting epidermal growth factor receptor in head and neck cancer , 2003 .

[3]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[4]  J. Baselga.  Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.

[5]  P. Harari,et al.  Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. , 2002, Molecular cancer therapeutics.

[6]  Roy S Herbst,et al.  Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.

[7]  K. Ang,et al.  C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. , 2001, International journal of radiation oncology, biology, physics.

[8]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.

[9]  J. Mendelsohn.  The epidermal growth factor receptor as a target for cancer therapy. , 2001, Endocrine-Related Cancer.

[10]  S. Spencer,et al.  Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Modjtahedi,et al.  Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase‐9 expression and in vitro invasion , 2000, International journal of cancer.

[12]  N R Hunter,et al.  Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  G. Poissonnet,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0297 , 2022 .

[14]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M. Groch,et al.  CLINICAL VALIDATION OF A QUANTITATIVE IMAGING-MIRD DOSIMETRY SOFTWARE APPLICATION: RETROSPECTIVE APPLICATION TO ANTI B-CELL LYMPHOMA MAB STUDIES. , 1998 .

[16]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[17]  G. Denardo,et al.  A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. , 1996, Nuclear medicine and biology.

[18]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  N. Goldstein,et al.  Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Kay,et al.  Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? , 1994, Clinical and diagnostic laboratory immunology.

[21]  F Demard,et al.  Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Mendelsohn,et al.  Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. , 1993, Cancer research.

[23]  J. Mendelsohn,et al.  Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. , 1986, Cancer research.

[24]  B. Gusterson,et al.  Over‐expression of the EGF receptor is a hallmark of squamous cell carcinomas , 1986, The Journal of pathology.

[25]  A. Lobuglio,et al.  Human immune response to monoclonal antibodies. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[26]  W. Gullick,et al.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.

[27]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[28]  P. Blondeau,et al.  Dimerization of an intermediate during the sodium in liquid ammonia reduction of l-thiazolidine-4-carboxylic acid , 1967 .

[29]  S. Ratner,et al.  The Action of Formaldehyde upon Cysteine , 1937 .